karyopharm therapeutics inc
(KPTI:Consolidated Issue Listed on NASDAQ Global Select )
Christopher Kirk Ph.D.
Member of Scientific Advisory Board, Karyopharm Therapeutics, Inc.
|Age||Total Calculated Compensation||This person is connected to 14 board members in 1 different organizations across 1 different industries.|
See Board Relationships
Dr. Christopher Kirk, Ph.D. serves as Vice President of Research at Onyx Pharmaceuticals, Inc. At Proteolix, Dr. Kirk played a key role in the discovery and early development of carfilzomib. Prior to joining Proteolix, Dr. Kirk held positions in drug discovery in inflammation at Affymax, Inc. and in target discovery in inflammation and oncology at Deltagen, Inc. Dr. Kirk held numerous positions in target and drug discovery as well as preclinical development in the biotechnology ...
85 Wells AvenuePhone: 617-658-0600
Newton, Massachusetts 02459
Board Members Memberships*There is no Board Members Memberships data available.
University of Michigan
Annual Compensation*There is no Annual Compensation data available.
Stock Options*There is no Stock Options data available.
Total Compensation*There is no Total Compensation data available.
|There is no Competitor Compensation data available.|